Renau-Mínguez Chantal, Herrero-Abadía Paula, Ruiz-Rodriguez Paula, Sentandreu Vicente, Torrents Eduard, Chiner-Oms Álvaro, Torres-Puente Manuela, Comas Iñaki, Julián Esther, Coscolla Mireia
I2SysBio, University of Valencia-FISABIO Joint Unit, Paterna, Spain.
Genetics and Microbiology Department, Faculty of Biosciences, Autonomous University of Barcelona, Barcelona, Spain.
Front Microbiol. 2023 Jan 5;13:982679. doi: 10.3389/fmicb.2022.982679. eCollection 2022.
is a rapid-growing, non-pathogenic species, originally isolated from environmental and human samples in Barcelona, Spain. is not pathogenic and it's phenotype and immunogenic properties have been well characterized. However, the knowledge of its underlying genetic composition is still incomplete. In this study, we first describe the 4 Mb genome of the . type strain ATCC 51384 assembling PacBio reads, and second, we assess the low intraspecies variability by comparing the type strain with Illumina reads from three additional strains. genome is composed of a circular chromosome with a high GC content of 69.2% and containing 3,791 CDSs, 97 pseudogenes, one prophage and no CRISPR loci. has shown no pathogenic potential in experiments, and our genomic analysis confirms its phylogenetic position with other non-pathogenic and rapid growing mycobacteria. Accordingly, we determined the absence of virulence-related genes, such as ESX-1 locus and most PE/PPE genes, among others. Although the immunogenic potential of . was proved to be as high as BCG, the only mycobacteria licensed to treat cancer, the genomic content of . T cell and B cell antigens in . genome is considerably lower than those antigens present in . BCG genome. Overall, this work provides relevant genomic data on one of the species of the mycobacterial genus with high therapeutic potential.
是一种快速生长的非致病性物种，最初从西班牙巴塞罗那的环境和人类样本中分离出来。它不具有致病性，其表型和免疫原性特性已得到充分表征。然而，对其潜在遗传组成的了解仍然不完整。在本研究中，我们首先描述了该物种4兆碱基的基因组，通过组装PacBio读段获得该物种模式菌株ATCC 51384的基因组，其次，我们通过将模式菌株与来自另外三个菌株的Illumina读段进行比较，评估种内低变异性。该物种的基因组由一条环状染色体组成，GC含量高，为69.2%，包含3791个编码序列、97个假基因、一个前噬菌体且无CRISPR位点。在实验中该物种未显示出致病潜力，我们的基因组分析证实了它与其他非致病性和快速生长的分枝杆菌的系统发育位置。因此，我们确定其不存在与毒力相关的基因，如ESX-1位点和大多数PE/PPE基因等。尽管该物种的免疫原性潜力被证明与卡介苗一样高，卡介苗是唯一被许可用于治疗癌症的分枝杆菌，但该物种基因组中的T细胞和B细胞抗原含量明显低于卡介苗基因组中的那些抗原。总体而言，这项工作提供了关于具有高治疗潜力的分枝杆菌属物种之一的相关基因组数据。
